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US / EU play key roles in vaccines innovation, 
development, production, and supply
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Vaccine Business Operation Locations 
now and future
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At present                     In future











Historical Path of China Immunization Programs
• In 1930s: Basically no immunization activities. Smallpox, diphtheria, 
pertussis, measles and polio infectious diseases caused annual incidence of 
more than 10 million.
• 1950s to 1980s: Vaccination with smallpox, BCG, diphtheria, polio, 
measles, PDT and tetanus vaccines resulted in significantly decrease in 
incidence rate.
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• In 1980s: Started the implementation of national immunization program, 
and involved in WHO EPI. The vaccination rate of BCG, polio, measles and 
DPT vaccines for infant reached 85%.
• In 1990s: Achieved the eradication of polio and neonatal tetanus, and 
implemented comprehensive child immunization services.
• 2008: Hepatitis A, meningitis, encephalitis B and MMR etc vaccination had 
been included into national immunization programs (EPI). Up 2010, the 
programs cover 14 kinds of vaccines that prevent up to 15 different 
infectious diseases.
China Vaccination Rate (97.4~99.4%)
1 year old children data from 2000 to 2008
Vaccination rate (%) of 1 year old children in China from 2000 to 20008
11Source: China SFDA
Current Landscape of Vaccines Market and 
Supplies in China
• China is currently the biggest vaccine producer and consumer1,2
– 43 vaccine supply companies1
– ~1,000 mm doses of 49 vaccines delivered every year3
– 1.341 billion people4 （up to 2011）
– ~201,5 million babies born every year
20% of total world 
vaccines supplies
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• China's vaccine sector is growing fast
– ~20 (156-257) percent growth annually 
– ~ $1.2-1.4 billion market size up to 20126,7,8
Sources:
1. Vaccine Development in China, BioPharm International, YB Zhou, 2007
2. China Vaccine Industry Report, 2008-2009, ResearchInChina, 2009
3. Public Markets for Vaccines, Bill Gates Foundation, 2010
4. Xinhua Beijing, 2011
5. National Population and Family Planning Commission, Jiang Fan, 2007
6. Vaccine Manufacturing Quality Control System and Risk Management Workshop, SFDA, 2010
7. China's Vaccine Sector. Report from Zero2IPO, a Chinese venture-capital firm 2010
8. business.ezinemark.com 2011
2000-2010 China Population Growth 


























Source: China vaccine market analysis report 2011 (version in Chinese)
~20 mm new born babies every year
China Pharmaceutical and Vaccine Markets
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Public market adoption (EPI) in China is 
expected to grow at 4x the rate of that in India
15
1.2009 Tender information, Hainan, Shanxi and Hunan Province for existing vaccines; 2/3 current PAHO pricing assumed for new vaccines
2.2009 UNICEF pricing for existing vaccines; Penta, Rota, and PCV based off of GAVI investment case
Source: EPI adoption timing based of off in market interviews
Bill Gates Foundation 2010 Report on Key Public Markets for Vaccines
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“China’s vaccine industry is well-developed”
Provide mainly
Category 1 vaccines
(EPI: paid by government)
Provide mainly
Category 2 vaccines
(Non-EPI: paid by individual)
Private/Public  Companies MNC  CompaniesState – Owned Companies
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Bill Gates Foundation 2010 Report on Key Public Markets for Vaccines
Vaccine Supplies in China
Category 1 vaccines
EPI (paid by Government)
Category 2 vaccines
(paid by individual)
Total shared doses (%) 80％ 20％
Total shared revenue (%) 40％ 60％
Sale growth rate 15％ 28％
Profit margin Small (fixed, low price) Large (high price)
China Vaccine Supplies Status
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# of diseases covered 15 rest  diseases
# of vaccine kinds 14 rest vaccines
Total supplies needed large and stable varies
Dominated Enterprises
China National Biotech Group
（CNBG)’s 6 companies
5 MNCs and 30+ local 
companies
In fact, the compulsory and free EPI vaccines are dominant in inoculation vaccines in China on account of relatively low 
economic level and comparatively lower awareness of epidemic precaution. Taking human vaccine market for example, the 
release of EPI human vaccines reached 648.4261 million person doses in 2009, accounting for 80.4% of the total; while the 
extra EPI vaccine was only 158.512 million person doses, with a share of 19.6%. Yet, the sum of EPI vaccine only occupied 
38.9% of the total being restricted by governmental procurement price, while the extra EPI vaccine covered 61.1%.
Source: Annals, ResearchInChina 
Europe and China Vaccines Suppliers
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China 43+ ?
Eur Vaccine Mfg： Vaccines: a Strategic Industry for Europe， Hock 2007；
China Today， Vaccine Development in China, Zhou 2007
The vast majority of vaccine doses are 
manufactured in Europe
China production: ~1,000,000,000 doses




Bill Gates Foundation 2010 Report on Key Public 
Markets for Vaccines:
Key Countries
1.India – emerging domestic market, strong export capability
2.China – strong domestic market, limited role in exporting vaccines
3.Brazil – strong domestic market, limited role in exporting vaccines
21
Purchasing Channels (WHO prequalification required)
1.GAVI – income based inclusion of poorest countries, UNICEF 
procurement.
2.PAHO – regional purchasing through revolving fund
It may take some time
“China's vaccine makers are gearing up over the next few 
years to push exports, which should lower costs of life 
saving immunizations for the world's poor, and provide 
major new competition for the big Western companies.”
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“However, it may take some time before some parts of the 
world are ready to embrace Chinese vaccine products 
when safety is as sensitive an issue as it is with 
vaccines — especially given the food, drug and other 
scandals the country has seen.”
“The world should get ready for a new Made in China product — vaccines”.
The Associated Press， 29 Nov 2011 by GILLIAN WONG
Chinese vaccines industry entering world market
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It may take time to achieve 
the goal with full confidence
China's Long March to Innovation Success
• “China’s journey from a seriously poor, 
autarkic, economy to the ‘shop floor of 
the world’, took a bit more than two 
decades.” 
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• “Today, less than a decade later, it 
appears poised to evolve into becoming 
a leading global innovator; but can 
China actually make this next great leap 
forward? ”
Bill Fischer, Forbes, 
“Ideas, Innovation, 
Globalization, & China” 
7/2011


















































































































































































Source: IMF, Xinhua, Standard Charter & Time
Cars
18 mm
TOP 1Internet Users       Rail road

















World Top 1 or 2
 “China medicine market today is 
about $8 billion (2005) and projected 
to grow to $24 billion by 2010”
 “China is No. 10 worldwide now, 
already quite something, and could 
China’s Economic Growth in Western’s Eyes in 2005
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be the 3rd one.”
 “It grows currently at 20%, faster   
than the average market growth.”
 “….. is good in chemistry and so 
forth, but I believe this place (China) 
probably has more potential.”
Daniel Vasella, Chairman and CEO, Novartis 2005




































Source: China pharmaceutical market analysis report 2010
World Pharmaceutical Market by 2020
2007 2009 2011 2020
1. US 1. US 1. US 1. China
2. Japan 2. Japan 2. China 2. US
3. France 3. France 3. Japan 3. Japan
4. Germany 4. Germany 4. Germany 4. Germany
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5. UK 5. China 5. France 5. France
6. Italy 6. Italy 6. Italy 6. Italy
7. Spain 7. Spain 7. Spain 7. Spain
8. Canada 8. UK 8. Brazil 8. Brazil
9. China 9. Brazil 9. US 9. US
10. Brazil 10. Canada 10 Canada 10 Canada


































China is leading the expansion of higher education
Nature 472, 276-279 (2011) 
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SOURCE: OECD/CHINESE MINISTRY OF EDUCATION









Number of Ph.D. Awarded
Chinese Oversea Returnees Changing the Way 







































































A total of 430,000 oversea returnees in last 
5 years including 150,000 in life science
China Lead in Global Life Sciences Supply Chain
70% of the surveyed companies ww have suppliers in China
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Wynn Bailey, Contract Pharma Jan-Feb 2011









Number of publications 
in the highly critical field 
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RN Kostoff, The Scientist, 18(18) 2004
of nanotechnology for 
top 20 countries during 
Jan-Sept 2004





























Over 49 Vaccines on China market
(in-complete list)



















• Influenza vaccine(whole virion)










• Brucellosis, Percutaneous Scarification
• Plague,Percutaneous Scarification
• Anthrax,Percutaneous Scarification
• Meningococcal Polysaccharide A
• Meningococcal Polysaccharide A+C








Structure of China Vaccine Technologies
Accumulated with 60 years of vaccine experience
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Main Traditional Vaccines
Hepatitis B, JE, Rabies, Flu, Acellular Pertussis vaccines
Improved Vaccines
Men AC Conjugate, Combination
HIB Conjugate, MenACW135Y vaccines
Nasal spray & Human-bird flu
Recombinant flu
Purified DPaT vaccines





Traditional Vaccines discovery research
Good in development
Vaccine Market Growth Driven by Innovation
Traditional vaccine’s growth: ~ 11% per year
$23.8 bn






















218 Vaccine Clinical Trials Approved by SFDA 
(2004 – 2012)
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A total of 28 different types of vaccines
# of Clinical TrialsSource of Data: China SFDA web




































Source of Data: China SFDA web
• HIV Phase II
• H1N1 Flu  approved
• HEV approved
• H. Pylori Phase III
Examples of novel and bio-similar 
vaccines under development in China
• HPV Phase I, II
• Pneum C. Phase I








Source of Data: China SFDA web
2011 publications: “China prepares to enter world vaccine 
market：lower costs, increased competition expected”
“The world should get ready for a new Made in China product — vaccines”.
The Associated Press， 29 Nov 2011 by GILLIAN WONG
“Could your vaccines soon be ‘Made in China’ ?”
The Associated Press， 29 Nov,2011 by Liz Klimas
“Rapid growth of the global vaccine market has great potential in China 
market for vaccines” 
Tweet, 1 Jan, 2011 by Gaga
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New Progresses of SFDA and WHO in China
• Concluded the qualification of 
SFDA quality monitoring system 
for vaccines on March 1, 2011
45
• Started “New GMP” (2010V) 
Implementation to meet 
international quality standard on 
March 1, 2011, with a deadline 








A. Na tiona l Re gula tory Syste m 7 7 95.45%
Function 1: Ma rke ting Authoriza tion and Licensing 
9 9 96.30%
China 13 - 17 Dec 2010
WHO Assessment on SFDA Quality Monitoring 
Systems through 52 indicators
46
a ctivitie s
Function 2: Post-ma rke ting a ctivities including surve illance  
of Adve rse  Eve nts Following Immuniza tion (AEFI)
8 8 96.00%
Function 3: NRA Lot re le ase 6 6 100.00%
Function 4: Labora tory a ccess 10 10 100.00%
Function 5: Regula tory inspe ctions 6 5 89.58%
Function 6: Regula tory ove rsight of clinica l tria ls 6 6 95.00%
Total of 52 indicatorsSource: SFDA public presentation 2011
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Status of Implementation of New GMP quality 
system in China
 4900 Pharma and Biopharma/Biotech Companies making 19336 
medicine products
 517 (11%) have passed new GMP required qualification inspections
 43 vaccine companies making 172 vaccine products
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 8 (19%) have passed new GMP required qualification inspections
 Changchun Institute of Biological Products Co., Ltd.
 Shenzhen Sanofi Pasteour Biologcal Products Co., Ltd.
 Chengdu Institute of Biological Products Co., Ltd.
 Hualan Biotechnology Company
 Wuhan Institute of Biological
 Shenzhen Kangtai Biological Products Co., Ltd.
 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. (a Novartis company)
 Beijing Xiangrui Biologcal Products Co., Ltd.
 Zhejiang Pukang Biotechnology Co.,Ltd. 
 All remaining companies have to pass new GMP inspections and 
receive SFDA certificate by the end of 2013.
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China Vaccine Industry Faces New Changes & Challenges
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Men A and C                        Hib                              Rabies                    Hepatitis A       





























































































































Consolidation Results in Complementary 
Strength Enhancement
Capability of taking current market 
(currently product on market)
Government Relationship
(Capability of influencing on 
SFDA approval speed)
Capability of taking future 
market (R&D innovation and 
novel product pipeline) Future Leader of 
54
Strong marketing and 
Sale Force
(Capability of market penetration)





“Vaccine Market Access in China – M&A Paves 
the Way for Foreign Companies”
• “China is the largest vaccine consumer in the world. It 
is a closed market with a strong local vaccine industry, 
access to which is challenging for Western players.”
• “In order to penetrate the China market, partnerships 
with local vaccine companies are crucial for Western 
vaccine manufacturers.”
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• “ New GMP implementation will further increase M&A 
opportunities for multinationals.”





SFDA Approved 34 Vaccine Clinical Trials 

















GSK, Sanofi-Pasteur, and Novartis have already acquired or set up local vaccine 
production companies in China.
Sanofi-Pasteur, and Novartis have started vaccine R&D centers in China as well.
Source: China SFDA
“In China, Speeding Toward the Future”
“ Historically, most important vaccines have originated in Europe and 
the United States. Now, countries like Brazil, India and China are 
providing lower-cost versions of some of them. …… because countries 
like China have experience in making low-cost vaccines, they could be 
better at designing new ones in ways that make them low in cost from 
the very beginning.”
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“………. I was impressed at how quickly the (Chinese vaccine) industry 
is moving ahead. They really understand low-cost manufacturing, and 
they're getting their quality up to world standards. Over the next five to 
ten years, they have the potential to create many breakthrough 
vaccines, as well as to help get current vaccines to the world’s poorest 
people, ……... “
Bill Gates Travel Note, 2010
Building the Bridge
China World Market
Innovation, Quality,
WHO and Collaboration
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Thank You !
li_shi@wison.com
